It was later found that while imatinib effectively reduced activation of BCR-ABL and downstream activation of SFKs in specimens derived from patients with imatinib-sensitive CML, this agent had no effect on SFK activation in samples from resistant patients despite BCR-ABL inhibition. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.